Collectively, these results suggest that novel retinamides that function as dual inhibitors of AR and MNK signaling in androgen-dependent and castration-resistant PCa have great potential as novel therapeutics for treatment of advanced prostate cancer. This evidence concerns the gene AR and prostate cancer.